News
Home>News & Events>Publications>D-RSC>FDA: Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment Over the Spectrum of Disease
144
Related Posts
-
226th ENMC International Workshop: Towards Validated and Qualified Biomarkers for Therapy Development for Duchenne Muscular Dystrophy
-
PPMD blogs about D-RSC Annual Meeting
-
Towards Validated and Qualified Biomarkers for Therapy Development for Duchenne Muscular Dystrophy
-
Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
-
D-RSC Definitions